Welcome to our dedicated page for Scilex Holding Co SEC filings (Ticker: SCLXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Scilex Holding Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Scilex Holding Co's regulatory disclosures and financial reporting.
Scilex Holding Company notified the SEC that it cannot file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 by the prescribed due date of May 15, 2026. The company says it needs additional time to finalize financial statements, including the consolidation of Vivasor Holding Company, and expects to file the Form 10-Q on or before May 20, 2026 (the fifth calendar day following the prescribed due date). The notification was signed by CFO Stephen Ma and cites Rule 12b-25 relief for a short extension to complete the filing.
Scilex Holding Company is moving ahead with a previously declared special dividend of Dream Bowl Meme Coin I digital tokens to certain equity holders. Eligible record holders of common stock, specified warrants, Tranche B convertible notes, and Series A preferred stock as of April 30, 2026 will receive five Dream Bowl Tokens for each share of common stock held or underlying their securities.
The dividend is scheduled to begin paying on May 26, 2026, but the board may change the record or payment dates or revoke the dividend entirely. Holders must open a Datavault AI digital wallet and submit an Opt-In Agreement via the company’s dividend website to receive tokens. Scilex describes the Dream Bowl Token as a digital collectible with no equity, voting, or payment rights, initially valued at $0 per token as of May 8, 2026, and plans a future listing on the Biconomy cryptocurrency exchange.
Scilex Holding Company disclosed that indirect subsidiary ACEA Therapeutics agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings in a stock acquisition valued at $1,000,000,000.
ACEA Therapeutics will receive 100,000,000 newly issued Phoenix shares at $10.00 per share and is expected to own about 82% of Phoenix after closing. The transaction, unanimously approved by the boards, is expected to close by the end of the second quarter of 2026, subject to Hart-Scott-Rodino antitrust clearance, Nasdaq-related approvals and other customary conditions.
Scilex Holding Company entered into a binding term sheet with Datavault AI Inc. for a proposed cash contribution and revenue participation arrangement tied to Datavault’s planned Quantum-Ready Edge Network in about 100 U.S. cities.
Scilex expects to make an upfront cash contribution of $120,000,000, paid in multiple closings with the final closing no later than December 31, 2026. In return, Datavault would pay Scilex 30% of Network Revenues until payments total $250,000,000, then 15% until combined payments reach $1,200,000,000, and 5% of Network Revenues for the remaining lifetime of the GPUs purchased with the upfront funds. The arrangement remains subject to negotiation and execution of definitive agreements, satisfaction of customary closing conditions, and achievement of specified operational and financial milestones, and may ultimately not be completed.
Scilex Holding Co director and CFO Stephen Hoi Ma reported an open-market purchase of 650,000 warrants. Each warrant was bought at $0.1538 and gives the right to buy one share of common stock at an exercise price of $1.20 per share.
The warrants were acquired on April 17, 2026 and are scheduled to expire on June 18, 2029. Following this transaction, Ma holds 650,000 warrants, each exercisable for one share of Scilex common stock.
Scilex Holding Co executive Henry Ji reported mixed warrant trades. On April 16, 2026, he made an open-market purchase of 3,250,000 warrants at $0.1538 per warrant, each exercisable at $1.20 for common stock. On April 17, 2026, he sold 650,000 warrants at the same price, leaving 2,600,000 warrants held directly, expiring on June 18, 2029.
Scilex Holding Company filed a Form S-3 to register up to $500,000,000 of securities on a shelf. The shelf prospectus permits offers of common stock, preferred stock, debt securities, warrants, rights and units in one or more offerings. The document describes existing commercial products (ZTlido, ELYXYB, GLOPERBA), pipeline assets (SP-102, SP-103, SP-104), certain corporate history and governance provisions, and states proceeds are intended for working capital and general corporate purposes.
Scilex Holding Company entered into a Warrant Agreement with Oramed Pharmaceuticals under which Oramed deferred an amortization payment on Scilex’s Tranche B senior secured convertible note that had been scheduled for October 1, 2025. In exchange, Scilex agreed to issue Oramed a new warrant to purchase 100,000 shares of common stock at an initial exercise price of $20.00 per share, called the February 2026 Warrant. The deferred amortization payment was ultimately made in November 2025, and the warrant is immediately exercisable and expires on December 13, 2029.
Scilex committed to file a registration statement to register the resale by Oramed of the shares issuable upon exercise, or to include them in another Form S-3. The warrant includes price-adjustment mechanisms, subject to a floor of $8.22 per share, a beneficial ownership cap initially at 4.99% (optionally adjustable up to 9.99% with notice), cashless exercise if no effective registration is available, and change-of-control protections allowing Oramed to require cash repurchase based on Black Scholes value.